Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients

The Impact of Intravitreal Injection of Anti-vascular Endothelial Growth Factor Faricimab on Renal Function in Patients With Diabetes Mellitus

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients. Faricimab is a new anti-VEGF drug which inhibits both VEGF-A and Ang-2 and it is used for the treatment of diabetic macular edema and neovascular age related macular degeneration. It is known that previous anti-VEGF agents has systematic absorption and may cause deterioration in renal function of the patients. However, the effect of Faricimab on kidney function has not been investigated yet. Taking into account that Ang-2 has destructive effect on kidneys, the investigation of the effect of its inhibition in diabetic patients who have already renal function deterioration may provide a valuable information in scientific community.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients with diabetes - Patients with DME or nAMD or macular edema secondary to retinal vein occlusion - Patients already receiving nephroprotective drugs Who Should NOT Join This Trial: - Patients with end stage renal disease - Pregnancy - Patients with other retinal disorders - Previous renal transplantation Patients under hemodialysis Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients with diabetes * Patients with DME or nAMD or macular edema secondary to retinal vein occlusion * Patients already receiving nephroprotective drugs Exclusion Criteria: * Patients with end stage renal disease * Pregnancy * Patients with other retinal disorders * Previous renal transplantation Patients under hemodialysis

Treatments Being Tested

DRUG

Intravitreal injection of Faricimab or Aflibercept 2 mg

Anti-VEGF agents Faricimab (Vabysmo) or Aflibercept 2 mg (Eylea) will be delivered intravitreally

Locations (2)

University Hospital of Alexandroupolis
Alexandroupoli, Evros, Greece
University Hospital of Alexandroupolis
Alexandroupoli, Greece